Ayala Pharmaceuticals

Targeted Therapies for People with Rare Cancers

Health Tech & Life Sciences
Acquired by Advaxis on Jan, 2023

Company Overview

Snapshot

Founded in January 2017, Ayala Pharmaceuticals operates with 11–50 employees. The company has raised a total of $102 million across 5 funding rounds from 6 investors. In May 2020, Ayala Pharmaceuticals completed an Initial Public Offering on NASDAQ, raising $55 million.

Business overview

Ayala Pharmaceuticals is a clinical-stage precision oncology company focused on developing and commercializing small molecule therapeutics for patients with rare and aggressive cancers, particularly those with genetically defined patient populations. The company's core technology involves product candidates like AL101 and AL102, which target cancer by inhibiting the aberrant activation of the Notch pathway using gamma-secretase inhibitors (GSIs). This approach enables personalized therapy for cancer patients, serving the pharmaceuticals and life sciences markets within the Health Tech & Life Sciences sector.

Strategic signal

In May 2024, Ayala Pharmaceuticals filed Form 15 to voluntarily deregister and suspend its reporting obligations. This move signals a significant shift in the company's public market presence and regulatory commitments, indicating a potential strategic re-evaluation or integration following its acquisition activities.

Company Intelligence Q&A

What was a significant recent corporate action by Ayala Pharmaceuticals?
In May 2024, Ayala Pharmaceuticals filed Form 15 to voluntarily deregister and suspend its reporting obligations, indicating a change in its public market status.
When did Ayala Pharmaceuticals complete its merger with Advaxis?
Ayala Pharmaceuticals completed its merger with Advaxis on January 19, 2023, with Advaxis being the acquiring entity.
Did Ayala Pharmaceuticals undergo a reverse merger recently?
Yes, in October 2023, Ayala Pharmaceuticals completed a reverse merger with Biosight.
When did Ayala Pharmaceuticals conduct its Initial Public Offering?
Ayala Pharmaceuticals completed its Initial Public Offering on NASDAQ in May 2020, raising $55 million.
Which investors participated in Ayala Pharmaceuticals' May 2019 funding round?
In May 2019, Ayala Pharmaceuticals received funding from investors including Novartis.

External links